Our latest take on CryoCell (USA Stocks:CCEL) analyst consensus
 | By Vlad Skutelnik | Macroaxis Story |
CryoCell International (CCEL) is a company in the Medical Care Facilities industry, specifically providing Health Care Providers & Services. The firm, with a market value of $6.5M, has shown strong performance metrics that may present a lucrative investment opportunity. The company's total revenue stands at an impressive $30.3M, with a profit margin of 0.0876 and an operating margin of 0.1496. Its net income from continuing operations is $2.8M, while the cost of revenue is $8.8M. Despite a negative net interest income of $1.5M, CryoCell's income before tax is a solid $3.3M, with an income tax expense of $547.5K. The company's current deferred revenue is $9.6M, reflecting a strong future income stream. The company's 52-week high and low are $8.12 and $2.69 respectively, with a 200-day moving average of 4.623 and a 50-day moving average of 5.3398. CryoCell's risk-adjusted performance is 0.1513, with a market risk-adjusted performance of 0.8645 and a Treynor ratio of 0.8545. The total risk alpha is 1.25, indicating the company's ability to generate excess returns for the level of risk taken. The analyst consensus for CryoCell is a strong buy, with an estimated target price value of $10. This presents a potential upside of 9.84, far outweighing the possible downside price of 0.065. The valuation real value is $7.9, indicating that the stock may be undervalued. In conclusion, CryoCell International appears to be a potentially lucrative investment opportunity, with strong financial performance, promising future revenue, and a strong buy analyst consensus. CryoCell International is set to announce its earnings tomorrow, with the forthcoming quarterly report anticipated on July 10, 2023. Given the growing interest in the healthcare providers and services sector, it's logical to delve deeper into CryoCell International's financial performance. We will examine the factors that could potentially enable the company to maintain above-average margins, despite the current economic climate.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
The asset utilization ratio is an indicator that refers to the revenue generated for every dollar of assets a company currently holds. CryoCell International has an asset utilization ratio of 46.75 percent. This implies that the company is generating $0.47 for each dollar of assets. An increasing asset utilization ratio suggests that CryoCell International is becoming more efficient with each dollar of assets it uses for its daily operations.
Detailed assessment
CryoCell International (USA Stocks: CCEL) presents a potentially lucrative investment opportunity, with a notable Return On Assets of 4.78% and a healthy Profit Margin of 8.76%. Despite a net interest income reported as a loss of 1.5M, the company has managed to generate a Net Income From Continuing Operations of 2.8M. The firm's solid financial health is further indicated by its Total Revenue of 30.3M, significantly higher than its Cost Of Revenue at 8.8M. With a low Beta of 0.4071, CryoCell's stock demonstrates lower volatility compared to the overall market, making it a potentially safer bet for investors. The company's share price is currently near its 52 Week High of 8.12, indicating strong market confidence in its performance. What is the right price you would pay to acquire a share of CryoCell International? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.
What is happening with CryoCell International this year
Annual and quarterly reports issued by CryoCell International are formal financial statements that are published yearly and quarterly and sent to CryoCell stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as CryoCell International often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
CryoCell International Gross Profit
CryoCell International Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing CryoCell International previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show CryoCell International Gross Profit growth over the last 10 years. Please check CryoCell International's gross profit and other fundamental indicators for more details.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of CryoCell International. Please refer to our Terms of Use for any information regarding our disclosure principles.